Mohammed A. Albalawi
Taibah University,Saudi Arabia
Title: Molecular and Cytogenetic Markers in Acute Myeloid Leukemia
Biography
Biography: Mohammed A. Albalawi
Abstract
Acute myeloid leukemia (AML) is a disease of hematopoietic progenitor cells with acquisition of heterogeneous genetic abnormalities that cause abnormal cell growth, proliferation and differentiation. Cytogenetic abnormality is considered an important prognostic factor in AML patients. AML patients are prognostically classified into three groups (favorable, intermediate, and poor) based on their molecular and cytogenetic analysis. Clonal chromosomes alterations are detected in approximately 50-55% of adults with AML. However, 40% to 49% of adults and 25% of children with AML, have no detectable chromosomal abnormality can be found on standard cytogenetic analysis. These cytogenetically normal (CN) patients have been classified as an intermediate-risk. Recently, with the advent of next generation sequencing, different molecular genetic abnormalities have been found in AML such as DNMT3A, TET2, IDH1/2, NRAS, KRAS, BCOR, RUNX1, and WT1. However, the significance of many of these gene mutations is unclear.